Laurus Labs to invest €5 million in JV KRKA Pharma
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
The company received one observation in the Form-483
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Revenue increased 11.4 per cent to Rs. 8,545 crore
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Subscribe To Our Newsletter & Stay Updated